



IN THE CLAIMS

RECEIVED


DEC 05 2002

TECH CENTER 1600/2900

Please cancel claims 1-8, and 10.

Please amend the claims as follows:

9. (amended) A method of treating a neoplastic condition or toxicity ^{in a subject} associated with an alteration in sphingolipid metabolism ^{in a subject in need thereof} comprising administering an effective amount of a fumonisins analog of the formula:



Where is support for this? ^{clm. 39?}
there is nothing in clm. 39 which says "fumonisins analog"

C1 wherein the spacer group is selected from the group consisting of alkyl (straight chain or branched, C₁ - C₂₀), hydroxyalkyl (straight chain or branched, C₁ - C₂₀) or dihydroxyalkyl (straight chain or branched, C₁ - C₂₀); Z is selected from the group consisting of H, O, NH, NQ, NQC(O), NHC(O), CO₂, C(O)NH, and C(O)NQ, wherein Q is an alkyl (straight chain or branched, C₁ - C₆); W is selected from the group consisting of no substituent, H, alkyl (straight chain or branched, C₁ - C₆), aryl (phenyl, substituted phenyl such as substitution with alkyl (straight chain or branched, C₁ - C₆) or halo), C(O)(CH₂)_nCO₂H (where n= 1 - 6), C(O) (CH₂)_n CW'₂ CO₂ H, where W' is selected independently from H, alkyl (straight chain or branched, C₁ - C₆), aryl (phenyl, substituted phenyl such as substitution with alkyl (straight chain or branched, C₁ - C₆) or halo), and (CH₂)_n CO₂ H, wherein n= 1 - 6; X is selected from the group consisting of H, methyl, CH₂ OH (and esters thereof), CH₂ NQ'₂ (where Q' is selected independently from H, alkyl (straight chain or branched, C₁ - C₂₀), and acyl (C(O)Q" where Q" is an alkyl, straight chain or branched, C₁ - C₂₀)); and V and Y are independently selected from the group consisting of H or OH (and esters thereof).

C2 11. (amended) The method of Claim 9, wherein ^{the subject has} Neimann-Picks syndrome or Tay-Sachs disease ~~is treated~~.